CagriSema vs Orforglipron: Combination Injection Versus Convenient Pill

This comparison captures a classic trade-off: CagriSema is a powerful combination injection that produces far more weight loss, while orforglipron is a simple daily pill that’s already approved and available. CagriSema is investigational; orforglipron (Foundayo) is approved. On raw results, CagriSema wins decisively (about 22.7% versus 12.4%), but orforglipron wins on convenience and, crucially, on being obtainable today. Here’s how to weigh them.

Two Very Different Products

These drugs sit at opposite ends of the spectrum. CagriSema combines two injectable drugs (cagrilintide, an amylin analog, plus semaglutide, a GLP-1 drug) into one weekly shot, targeting appetite through two hormone pathways for maximum effect. Orforglipron is a once-daily oral pill activating GLP-1 alone, built around convenience. So one prioritizes power, the other ease.

Head to Head

Weight Loss: CagriSema Leads Clearly

On weight loss, CagriSema is far ahead. In its REDEFINE 1 trial, published in the New England Journal of Medicine in 2025, it produced about 22.7% average weight loss over 68 weeks. Orforglipron produces about 12.4% at its highest dose. That’s nearly double, reflecting CagriSema’s two-drug approach versus orforglipron’s single mechanism, and the general tendency for injections to outperform pills. If maximum weight loss were the only factor, CagriSema would be the obvious pick.

Convenience and Access: Orforglipron Leads

Here’s the counterweight. Orforglipron is a pill (no needles), can be taken any time of day with or without food, and, most importantly, is approved and available right now. CagriSema, despite its stronger numbers, is investigational and only accessible through clinical trials, though Novo Nordisk has filed for FDA approval. Consider a hypothetical patient who wants to start treatment this month and prefers pills: orforglipron is a real option today, while CagriSema isn’t available yet regardless of how impressive its data looks. A drug you can’t get can’t help you.

Who Might Prefer Which

Someone focused on maximum weight loss, comfortable with injections, and willing to wait for approval might favor CagriSema once available. Someone who wants an effective option now, prefers a pill, or dislikes needles would choose orforglipron. It’s a genuine trade-off between peak results and practical accessibility, not a simple ranking.

What This Means for You Right Now

CagriSema is not available, and TrimRx does not offer it. Orforglipron is available through its manufacturer. TrimRx offers its own set of options, including compounded semaglutide and compounded tirzepatide plus brand injectables like Ozempic, Wegovy, Mounjaro, and Zepbound. A provider can help you weigh whether an available pill, an available injection, or a compounded option best fits your goals while CagriSema completes its path to market.

Frequently Asked Questions

Is CagriSema or orforglipron more effective?

CagriSema produces significantly more weight loss (about 22.7% versus about 12.4% for orforglipron), because it’s a two-drug injection versus a single-mechanism pill. Orforglipron’s advantage is convenience and availability, not maximum efficacy.

Why choose orforglipron if CagriSema works better?

Orforglipron is an approved, convenient daily pill you can get now, while CagriSema is investigational and unavailable. For someone who wants to start soon, prefers pills, or dislikes injections, orforglipron is a real option today.

Can I get either now?

Orforglipron is FDA approved and available by prescription. CagriSema is investigational and available only through clinical trials. TrimRx offers approved alternatives including compounded and brand GLP-1 options.

To find what fits you today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. CagriSema is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.